



U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. Charles Keller 1321.2.83.1

10/530,512

APR 07 2006

INTERNATIONAL APPLICATION NO.

PCT/US03/32765

I.A. FILING DATE 10/15/2003

PRIORITY DATE 10/15/2002

21552 MADSON & AUSTIN **GATEWAY TOWER WEST** SUITE 900 15 WEST SOUTH TEMPLE SALT LAKE CITY, UT 84101



CONFIRMATION NO. 6728 371 FORMALITIES LETTER *OC000000018030484*

Date Mailed: 02/23/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- · A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

RESPONSE DUE

DARRELL C COTTMAN

Telephone: (703) 308-9140 EXT 203

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO
10/530,512	PCT/US03/32765	1321.2.83.1

FORM PCT/DO/EO/922 (371 Formalities Notice)



FU

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April ________, 2006

Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/530,512

Confirmation No.: 6728

Applicant

Charles Keller et al.

Title

HIGH THROUGHPUT DETECTION OF GLUTATHIONE S-

TRANSFERASE POLYMORPHIC ALLELES

Filed

:

April 6, 2005

TC/A.U.

(not yet assigned)

Examiner

(not yet assigned)

Docket No.

1321.2.83.1

Customer No.

21552

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF AND STATEMENT REGARDING SEQUENCE LISTING

Dear Sir:

This paper is being filed in response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed February 23, 2006. A substitute paper copy and computer readable copy of the sequence listing are enclosed herewith. This statement is being filed according to 37 CFR 1.821(f). The sequence listing information recorded in computer readable form is identical to the written sequence listing and includes no new matter.

A copy of the Notification to Comply with Requirements for Patent Applications

Containing Nucleotide and/or Amino Acid Sequence Disclosures is enclosed.



Date: April 4, 2006

MADSON & AUSTIN Gateway Tower West
15 West South Temple, Suite 900
Salt Lake City, Utah 84101
Telephone: 801/537-1700 Respectfully submitted,

Evan R. Witt

Reg. No. 32,512 Attorney for Applicants